LONDON (ShareCast) - (Sharecast News) - Analysts at Berenberg downgraded drugmaker GSK from 'buy' to 'hold' on Tuesday as it awaited upcoming product launches.
Berenberg said GSK has delivered 12% absolute share price performance year-to-date, the highest in the sector, but despite this, continues to trade roughly 30% below the value of its marketed drugs alone.

The German bank stated that a better-than-anticipated start to any of GSK's upcoming product rollouts could "reinvigorate investor interest" and begin to address 2028+ HIV patent expiry fears.

However, Berenberg expects investors to adopt "a show-me attitude" and noted that while GSK's valuation "remains unchallenging", it prefers Sanofi for pharma value investors.

"GSK trades on 8.7x 2026 adjusted earnings versus non-obesity European peers on 11.5x. On EV/NPV, GSK trades c15% below European non-obesity peers (0.70x versus 0.82x) and c30% below the value of marketed assets alone," said Berenberg, which reiterated its £16.00 target price.





Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE